ClinicalTrials.gg
CompletedNCT02207491Rocket-1Updated Apr 13, 2018Results posted

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

A Phase 3 interventional study of Timolol maleate Ophthalmic Solution 0.5% BID and AR-13324 Ophthalmic Solution 0.02% in Ocular Hypertension and Open-angle Glaucoma, sponsored by Aerie Pharmaceuticals. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2018-04-13.

Primary conditionGlaucoma, Open-AngleRegistry: Ocular HypertensionReclassifiedWhy we changed it
Registry
Ocular Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Ocular Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
411
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Enrollment
4th of 17
411 · median 85
Started
2014
with 1 other
Phase 3
5 of 17
none open now
Registered
3rd of 17
by date
Lead sponsor
11 of 17
Aerie Pharmaceuticals

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 4th largest by enrollment, is one of 2 that started in 2014, is one of 5 in phase 3, and was the 3rd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%

03

Conditions studied

  • Ocular Hypertension
  • Open-angle Glaucoma

Browse trials for

Keywords

  • Glaucoma
04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

This study's enrollment of 411 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

First submitted before Aerie Pharmaceuticals became part of Alcon.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subject Inclusion criteria:

  1. 0-2 years of age and 18 years or greater.
  2. Diagnosis of open angle glaucoma or ocular hypertension
  3. Unmedicated (post-washout) IOP (Intraocular Pressure) >20 mm Hg and \< 27 mm Hg in the study eye at 2 qualification visits.
  4. Corrected visual acuity in each eye equivalent to 20/200.
  5. Able and willing to give signed (parent or guardian consent for pediatric patient) and follow study instructions.

Subject exclusion criteria

Ophthalmic:

  1. Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.
  2. Intraocular pressure ≥27 mm Hg (unmedicated) in both eyes (individuals who are excluded for this criterion are not allowed to attempt requalification), or use of more than two ocular hypotensive medications within 30 days of screening. Note: fixed dose combinations count as two medications.
  3. Known to any component of the formulations to be used (benzalkonium chloride, etc.), to topical anesthetics or beta adrenoceptor antagonists.
  4. Previous glaucoma intraocular surgery or glaucoma laser procedures in either eye
  5. Refractive surgery in either eye.
  6. Ocular trauma in either eye within the six months prior to screening, or ocular surgery or non-refractive laser treatment within the three months prior to screening.
  7. Recent or current evidence of ocular infection or inflammation in either eye. Current evidence of blepharitis, conjunctivitis, or a history of herpes simplex or zoster keratitis at screening in either eye.
  8. Ocular medication in either eye of any kind within 30 days of screening.
  9. Clinically significant ocular disease in either eye (e.g., corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe.
  10. Central corneal thickness in either eye greater than 600 µm at screening.
  11. Any abnormality in either eye preventing reliable applanation tonometry of either eye.

    Systemic:

  12. Clinically relevant abnormalities (as determined by the investigator) in laboratory tests at screening which may impact the study.
  13. Known hypersensitivity or to beta-adrenoceptor antagonists (e.g., or bronchial asthma; abnormally low blood pressure or heart rate; second or third degree heart block or congestive heart failure; severe diabetes).
  14. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
  15. Participation in any study within 30 days prior to screening.
  16. Changes of systemic medication that could have an effect on intraocular pressure within 30 days prior to screening, or anticipated during the study.
  17. Women of who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of . An adult woman is considered to be of childbearing potential unless she is one year or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
411 participants (actual)

Study arms

  • Experimental
    AR-13324 Ophthalmic Solution 0.02% & Placebo

    1 drop AR-13324 in the evening (PM) \& 1 drop placebo in the morning (AM) in both eyes (OU)

    Drug: AR-13324 Ophthalmic Solution 0.02% · Other: Placebo

  • Active comparator
    Timolol maleate Ophthalmic Solution 0.5% BID

    1 drop Timolol maleate twice daily (BID) in the morning (AM) \& evening (PM) in both eyes (OU)

    Drug: Timolol maleate Ophthalmic Solution 0.5% BID

Interventions

07

What researchers measure

Primary outcomes

  1. Intraocular Pressure (IOP)

    The primary efficacy outcome is mean IOP

    Time frame: 3 months

Secondary outcomes

  1. Extent of Exposure

    Exposure to study medication in days for all treatment groups.

    Time frame: 3 months

08

Results

Posted Apr 13, 2018

Participant flow

Participants were recruited at 35 clinical trial sites starting in June of 2014. The first participant was enrolled in July of 2014 and the last participant was enrolled in December of 2014.

Participant flow — Overall Study
MilestoneAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BID
Started202209
Completed171196
Not completed3113
Withdrew: Adverse event204
Withdrew: Withdrawal by subject32
Withdrew: Non-compliant01
Withdrew: Lost to follow-up01
Withdrew: Lack of efficacy30
Withdrew: Physician decision20
Withdrew: Protocol violation35

Outcome measures

PrimaryIntraocular Pressure (IOP)

The primary efficacy outcome is mean IOP

Time frame:
3 months
Reported as:
Mean · mmHg
Intraocular Pressure (IOP)
mmHgAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BID
Day 1, 0800 hours23.42 ± 1.75623.37 ± 1.658
Day 1, 1000 hours22.28 ± 2.12821.92 ± 2.053
Day 1, 1600 hours21.78 ± 2.38521.45 ± 2.365
Day 15, 0800 hours18.68 ± 3.34218.33 ± 2.566
Day 15, 1000 hours17.29 ± 3.30317.55 ± 2.570
Day 15, 1600 hours17.24 ± 3.29417.70 ± 2.661
Day 43, 0800 hours19.35 ± 3.62918.24 ± 2.924
Day 43, 1000 hours18.14 ± 3.50217.44 ± 2.725
Day 43, 1600 hours17.86 ± 3.58017.71 ± 2.820
Day 90 (month 3), 0800 hours19.81 ± 3.64718.47 ± 2.711
Day 90 (month 3), 1000 hours18.92 ± 3.70217.96 ± 2.674
Day 90 (month 3), 1600 hours18.48 ± 3.59517.74 ± 2.546
Statistical analysis
  • AR-13324 Ophthalmic Solution 0.02% & Placebo vs Timolol Maleate Ophthalmic Solution 0.5% BID · ANCOVA · p = <0.0001 (Calculated p-value)Statistical analysis applies at all 3 timepoints on Day 15, Day 43, and Day 90
SecondaryExtent of Exposure

Exposure to study medication in days for all treatment groups.

Time frame:
3 months
Reported as:
Mean · days
Extent of Exposure
daysAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BID
Extent of Exposure82.8 ± 21.4487.4 ± 15.53

Adverse events

Collected over Adverse event data was collected during the course of the 90-day treatment period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AR-13324 Ophthalmic Solution 0.02% & Placebo0/203 (0%)3/203 (1.5%)145/203 (71.4%)
Timolol Maleate Ophthalmic Solution 0.5% BID0/208 (0%)4/208 (1.9%)75/208 (36.1%)
Most frequent serious events
Most frequent serious events
EventAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BID
Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2030/208
Exacerbation of Coronary Artery DiseaseCardiac disorders1/2030/208
HypertensionVascular disorders1/2030/208
Worsening of AdenomyosisReproductive system and breast disorders0/2031/208
Congestive Heart FailureCardiac disorders0/2031/208
Left Upper Extremity NumbnessNervous system disorders0/2031/208
Stroke (CVA)Nervous system disorders0/2031/208
PneumoniaInfections and infestations0/2031/208
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders0/2031/208
Most frequent other events
Most frequent other events
EventAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BID
Conjunctival hyperemiaEye disorders108/20317/208
Instillation Site PainGeneral disorders30/20342/208
Conjunctival HaemmorrhageEye disorders32/2032/208
Instillation Site ErythemaGeneral disorders24/2034/208
Vital Dye Staining Cornea PresentInvestigations17/20319/208
Cornea VerticillataEye disorders12/2030/208
Erythema of EyelidEye disorders12/2030/208
Vision BlurredEye disorders11/2031/208

Baseline characteristics

Randomized Population

Age, Continuous
Age, Continuous(years)AR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDTotal
Mean65.8 ± 11.6564.2 ± 11.3465.0 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)AR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDTotal
Female114136250
Male8873161
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDTotal
Hispanic or Latino272855
Not Hispanic or Latino175181356
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDTotal
American Indian or Alaska Native000
Asian246
Native Hawaiian or Other Pacific Islander000
Black or African American435194
White157153310
More than one race000
Unknown or Not Reported011
09

Study locations

1 site
  • Aerie Pharmaceuticals
    Bedminster, New Jersey 07921, United States
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 3 years 1 month after primary completion. A results delay was requested in Jul 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2014
First posted
Aug 4, 2014
Start
Jul 2014
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results delay requested
Jul 9, 2015
Results first posted
Apr 13, 2018
Last update
Apr 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02207491
Responsible party
Sponsor
First posted
Aug 4, 2014
Start date
Jul 2014
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Apr 13, 2018
Last update
Apr 13, 2018

Study contacts

Theresa Heah, MD
study director · Aerie Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion